Co-Authors
This is a "connection" page, showing publications co-authored by VIVEK SUBBIAH and JOUD HAJJAR.
Connection Strength
0.229
-
Author response to Cunha et al. J Immunother Cancer. 2021 07; 9(7).
Score: 0.051
-
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4).
Score: 0.051
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.047
-
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
Score: 0.040
-
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607.
Score: 0.040